Published on 29 Jan 2024 on GuruFocus.com via Yahoo Finance
Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares
In a recent transaction on January 31, 2024, CEO Sergio Traversa of Relmada Therapeutics Inc (NASDAQ:RLMD) purchased 100,000 shares of the company's stock, according to a SEC Filing. The transaction has been officially filed with the Securities and Exchange Commission.
Warning! GuruFocus has detected 1 Warning Sign with RLMD.
Relmada Therapeutics Inc is a clinical-stage biotechnology company focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The company aims to provide therapies that are both safer and more efficacious than existing opioid analgesics.